Sponsor Presentation: Medik8
Retinyl Retinoate : Now inside Dissolvable Microneedle Patches
Topical retinoids are a powerful, reliable and increasingly popular treatment modality in the treatment and management of skin wrinkles, pigmentation and acne vulgaris. In the realm of topical anti-ageing skincare, there is arguably little else that can match the long history of proven success that comes with regular use of ‘Vitamin A’ based formulations such as retinoic acid and retinol.
Retinoic acid and retinol can be nevertheless irritating to many users and skin irritation is the main reason given for low adoption/compliance of retinoic acid and retinol. Encapsulated retinyl retinoate , as published in numerous journals including the British Journal of Dermatology, is a novel and patented hybrid molecule made from the condensation reaction of retinol and retinoic acid. Results show it works both more quickly, and more effectively than ordinary retinol.
Retinyl retinoate has been shown to have a remarkably low irritation profile. Further, the molecule has greatly superior photo-stability meaning it can be used during the day as well as night leading to multiple benefits including a reduced peak-dosage profile - further reducing potential irritation.
Following publication of a 2014 study, Retinyl Retinoate has now been integrated into novel dissolving microneedle patches that are applied around the eye area. The lecture will discuss these results and how they can improve the speed and intensity of anti-ageing results from retinoids with much less or no irritation.
Elliot Isaacs, Founder, Pangaea Laboratories